Work

A phase I dose-escalation study of intraperitoneal (IP) cisplatin, IV/IP paclitaxel, IV bevacizumab, and oral olaparib for newly diagnosed adenxal carcinoma.

Year: 2017

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2017.35.15_suppl.5572

Authors: Jason A. Konner, Nicole N Boucicaut, Roisin Eilish O'Cearbhaill, Dmitriy Zamarin, Vicky Makker, Paul Sabbatini, William P. Tew, Karen Anne Cadoo, Rachel N. Grisham, Carol Aghajanian

Institutions: Memorial Sloan Kettering Cancer Center, Weill Cornell Medicine

Language: English

Topic: Ovarian cancer diagnosis and treatment

Subfield: Reproductive Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2890629775

Cites:

Cited by: 3

Related to: 10